TY - JOUR
T1 - Impact of prior treatment exposure on response to antidepressant treatment in late life
AU - Tew, James D.
AU - Mulsant, Benoit H.
AU - Houck, Patricia R.
AU - Lenze, Eric J.
AU - Whyte, Ellen M.
AU - Miller, Mark D.
AU - Stack, Jacqueline A.
AU - Bensasi, Salem
AU - Reynolds, Charles F.
N1 - Funding Information:
Dr. Lenze has received research support from Forest, Pfizer, and OrthoMcNeill. Dr. Miller has received honoraria from Forest, GlaxoSmithKline, and Wyeth. Dr. Mulsant has received research support, educational support, and honoraria from AstraZeneca, Bristol-Myers Squibb, Corcept, Eisai, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Lundbeck, and Pfizer. He is a non-major stockholder of Akzo-Nobel, Alkermes, AstraZeneca, Biogen Idec, Celsion, Elan, Eli Lilly, Forest, General Electric, Immune Response, and Pfizer. Dr. Reynolds has received research support from Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, and Pfizer. Dr. Whyte has received research support from Pfizer.
Funding Information:
This study was supported in part by USPHS grants P30 MH52247, P30 MH71944, R01 MH37869, R01 MH43832, R25 MH60473, K24 MH069430, and K23 MH64196 . Dr. Tew acknowledges the American Association for Geriatric Psychiatry Fellowship Program for its support.
PY - 2006/11
Y1 - 2006/11
N2 - Objective: The objective of this study was to describe the correlates of prior antidepressant exposure and its association with response to protocolized treatment in older patients with major depression. Methods: Based on their prior antidepressant treatment exposure, 193 elderly patients with a major depressive episode were divided into three groups: those with no prior treatment for their current episode (not treated [TN]), those with antidepressant trials of inadequate dose or duration ("treatment-inadequate" [TN]), and those with at least one adequate trial but persisting depression ("treatment- resistant" [TR]). All patients then received protocolized treatment with interpersonal psychotherapy (IPT) and paroxetine plus pharmacologic augmentation if needed. The demographic, clinical, and outcome information were compared among these three groups. Results: Approximately one-third of the patients referred to the study had been adequately treated (TR), one-third had been inadequately treated (TI), and one-third were not treated for the current episode (TN). Treatment completion rates and reasons for dropping out did not differ statistically among TR, TI, and TN patients. TR patients took longer to respond (13.0 weeks) than either TI or TN patients (7.6 and 8.0 weeks, respectively). TR and TI patients had lower response rates (67% and 71%) than TN patients (86%). Conclusions: Prior treatment exposure is an important correlate of course and outcome in late-life depression. Most TR and TI patients eventually respond, but TR patients may require more intensive and longer courses of treatment than TI and TN patients.
AB - Objective: The objective of this study was to describe the correlates of prior antidepressant exposure and its association with response to protocolized treatment in older patients with major depression. Methods: Based on their prior antidepressant treatment exposure, 193 elderly patients with a major depressive episode were divided into three groups: those with no prior treatment for their current episode (not treated [TN]), those with antidepressant trials of inadequate dose or duration ("treatment-inadequate" [TN]), and those with at least one adequate trial but persisting depression ("treatment- resistant" [TR]). All patients then received protocolized treatment with interpersonal psychotherapy (IPT) and paroxetine plus pharmacologic augmentation if needed. The demographic, clinical, and outcome information were compared among these three groups. Results: Approximately one-third of the patients referred to the study had been adequately treated (TR), one-third had been inadequately treated (TI), and one-third were not treated for the current episode (TN). Treatment completion rates and reasons for dropping out did not differ statistically among TR, TI, and TN patients. TR patients took longer to respond (13.0 weeks) than either TI or TN patients (7.6 and 8.0 weeks, respectively). TR and TI patients had lower response rates (67% and 71%) than TN patients (86%). Conclusions: Prior treatment exposure is an important correlate of course and outcome in late-life depression. Most TR and TI patients eventually respond, but TR patients may require more intensive and longer courses of treatment than TI and TN patients.
KW - Antidepressant therapy
KW - Depression
KW - Late-life
KW - Treatment-resistance
UR - http://www.scopus.com/inward/record.url?scp=33750686337&partnerID=8YFLogxK
U2 - 10.1097/01.JGP.0000222311.70424.85
DO - 10.1097/01.JGP.0000222311.70424.85
M3 - Article
C2 - 17068318
AN - SCOPUS:33750686337
SN - 1064-7481
VL - 14
SP - 957
EP - 965
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 11
ER -